Thomas Dyrberg

Thomas joined Novo A/S in 2000 and is currently a Senior Advisor. He is a member of the Boards of Directors of Galera Therapeutics, Inc., Nuvelution Pharma, Inc., Ophthotech Corporation, PanOptica Inc., and most recently, Allievex.

Thomas held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, USA. In 1990, he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development.

Thomas earned a MD degree from the University of Copenhagen in 1981, as well as a DMSc degree, also from the University of Copenhagen, in 1986.